Drugs that are metabolized to amphetamine or methamphetamine are potentially significant concerns in the interpretation of amphetamine-positive drug testing results. A number of different compounds have been reported to produce amphetamine in the urine of users. One of these compounds, fenproporex, has been shown to produce amphetamine. Previous reports indicate that the parent compound can be detected only for a few hours following administration, whereas the amphetamine can be detected for several days. Administration of fenproporex to five healthy volunteers resulted in amphetamine being detected in the urine of all subjects. Peak concentrations of amphetamine were detected at approximately 6-20 h postdose and ranged from approximately 1200 to 2100 ng/mL amphetamine. Amphetamine could be detected (>5 ng/mL) in the urine for up to 119 h. Analysis of the metabolically produced amphetamine showed the presence of both enantiomers, which can be helpful in the differentiation of some illicit amphetamine use from the use of this precursor drug. More significantly, all samples that contained amphetamine at a concentration of at least 500 ng/mL were shown to also contain measurable amounts of the parent compound.
phetamine, complications arise in the interpretation of amphetamine-positive drug tests. Previous studies indicate that the parent compound could be detected only for a few hours following administration, whereas the metabolically produced amphetamine could be detected for days.
In this study, fenproporex was administered to five healthy volunteers. As expected, amphetamine was detected in the urine of all subjects. Peak concentrations were detected from approximately 6-20 h postdose, depending on the individual. The amphetamine concentration in one individual reached a high of 2099 ng/mL. The present study showed that fenproporex could be detected for longer periods of time than previously reported. It also established the enantiomeric composition of metabolically produced amphetamine as a mixture of both enantiomers. Another significant finding of this study was that all samples containing amphetamine at concentrations greater than or equal to 500 ng/mL also had detectable amounts of fenproporex.
Materials and Methods

Introduction
Fenproporex, 3-[(1-methyl-2-phenylethyl)amino]-propanenitrile, is an anorectic drug that is available in a number of countries throughout the world (1) . It is available in Mexico as a prescription drug, although it is easily obtained without a prescription. Although classified as a nonstimulant anorectic agent, a study by Tognoni et al. (2) demonstrated that administration of fenproporex leads to formation of considerable amounts of amphetamine in the body via cleavage of the nitrogen-cyanoethyl bond ( Figure 1 ). That study also reported stimulant effects following administration of the drug, presumably due to the conversion to amphetamine. Because ingestion of fenproporex results in urinary excretion of am-* Author to whom correspondence should be addressed.
Materials
Amphetamine, methamphetamine, amphetamine-d5 (1-phenyl-2-aminopropane-1,2,3,3,3-D5), methamphetamine-d5 (1-phenyl-2-methyl-D3-aminopropane-1,2-D2), and methamphetamine-du (1-phenyl-Ds-2-methyl-D3-aminopropane-3,3,3- * Limit of detection = S ng/mL; limit of quantitation = 5 ng/mL. t Limit of detection = 5 ng/mL; limit of quantitation = 5 nB/mL. =~ Samples that contained feriproporex at or greater than the limit of detection (2 ng/mL) but at or less than the limit of quantitation (5 ng/mL) are indicated as detected. ' Limit of detection = 5 ng/mL; limit of quanlitation = 5 ng/mL. l" Limit of detection = 5 ng/mL; limit of quantitation = 5 n~mL. ~ Samples that contained feriproporex at or greater than the limit of detection (2 ng/mL) but at or less than the limit of quantilation (5 ng/mL) are indicated as detected.
was obtained from Alltech (Deerfield, IL). d-Amphetamine, dmethamphetamine,/-amphetamine, l-methamphetamine, and fenproporex were obtained from Sigma Chemical Co. (St. Louis, MO). The internal standards (amphetamine-d5 and methamphetamine-d~) used for enantiomeric characterization were racemic. The derivatizing reagents, heptafluorobutyric anhydride (HFBA) and N-trifluoroacetyl-l-prolyl chloride (L-TPC), were obtained from Sigma and Regis Chemical Co. (Morton Grove, IL), respectively. Fenproporex administered to experimental subjects, in the form of Fenisec, was purchased from a pharmacy in Mexico.
Drug administration and sample collection
Ten milligrams of fenproporex in the form of a single Fenisec tablet was administered orally to five healthy volunteers with no Journal of Analytical Toxicology, Vol. 20, October 1996 history of amphetamine, methamphetamine, or fenproporex use. Following administration, urine was collected for the next five days. Samples were provided ad lib, and total void was measured to assess percentage conversion to amphetamine. Following collection, samples were refrigerated until analysis. No attempt was made during this study to physiologically control urine pH.
Sample preparation and analysis
Sample pH was measured using a Fisher (Pittsburgh, PA) accumet model 50 pH meter, and specific gravity was determined using an AD Scientific Instruments model H011 refractometer. Creatinine levels were determined at the Wilford Hall Medical Center clinical laboratory using standard clinical laboratory procedures. Gas chromatographic-mass spectrometric (GC-MS) analyses were performed using a Hewlett-Packard Quantitative analysis. Quantitation was based on single-point calibration using a calibration standard at 500 ng/mL of amphetamine, methamphetamine, fenproporex, and internal standard. Amphetamine and methamphetamine were quantitated using their deuterated isotopomer as the internal standard. Fenproporex was quantitated using deuterated methamphetamine. Low concentration samples were quantitated based on singlepoint calibration using a standard at 25 ng/mL of each of the analytes of interest and 50 ng/mL of internal standards. Aliquots (2 mL) were extracted, derivatized with heptafluorobutyric anhydride (HFBA), and analyzed by GC-MS as previously described (3) with the additional monitoring of ions at rn/z 293, 118, and 56 for purposes of detection of fenpmporex.
Enantiomer analysis. Urine samples (2 mL) containing 500 ng/mL each of amphetamine-d5 and methamphetamine-d5 were analyzed. Extraction was accomplished by addition of 0.3 mL 1M NaOH and 5 mL 1-chlorobutane. Tubes were shaken for 10 rain at approximately 120 cpm and then centrifuged for 5 min at approximately 1500 rprn to separate the layers. The organic layer was transferred; 50 pL of N-trifluoroacetyl-l-prolyl chloride was added and then allowed to stand at room temperature for 15 min. NaOH (3 mL, 0.01M) was then added, and the samples were shaken for 15 min and centrifuged as described previously. The organic layer was transferred, evaporated under ni- This assay provides qualitative determination of the enantiomeric composition of amphetamine and methamphetamine. Each batch of samples was calibrated using a sample containing 50% of both enantiomers of amphetamine and methamphetamine. The samples were analyzed with control samples containing 0% l-enantiomer plus 100% d-enantiomer of amphetamine and methamphetamine; 100% l-enantiomer plus 0% d-enantiomer of amphetamine and methamphetamine; and a control containing no amphetamine or methamphetamine.
Results and Discussion
As previously reported (2, (4) (5) (6) (7) (8) , ingestion of fenproporex resulted in the excretion of amphetamine in the urine. No indication of methamphetamine was seen in any of the samples (LOD for methamphetamine, 5 ng/mL). Following administration of the drug, the subjects were asked if they noticed any sub- jective effect from the drug. The subjects reported no sensation of stimulation following administration. One subject reported a mild episode of light-headedness several hours following administra-3 tion. It was unclear whether this was the consequence of taking the drug, or of the fact the subject had gone several hours past his normal noon meal time without eating. Another subject reported a mild loss of appetite for a short period of time.
The quantitative results of the samples are shown in Table I . Figure 1 shows the structure of fenproporex, revealing its relation7So ship to amphetamine. Figure 2 illustrates a typical chromatographic result from the quantitative analysis of subject samples. Fenproporex is easily detected using the same extraction, derivatization, and instrumental analysis parameters used for the determination of amphetamine and methamphetamine. Linearity was obtainable from 5-2500 ng/mL for this drug. The limit of detection for fenproporex was determined to be 2 ng/mL (acceptable ion ratios, acceptable retention time, and signal-to-noise ratio ___ 3:1). Fenproporex was shown to elute after methamphetamine (relative retention time, 1.39 min on HP-1, 1.79 min on DB-17). The enantiomeric composition of the metabolically produced amphetamine is illustrated in Figure 3 , which clearly demonstrates the presence of both enantiomers in an example chromatogram from one subject's urine. Amphetamine could be detected in the urine of all subjects following the administration of the drug. Peak concentrations of amphetamine were seen in samples collected 5:50-20:20 h postdose where the concentrations reached 1201-2099 ng/mL. Although previous studies clearly established the presence of amphetamine following fenproporex administration, none delineated peak urine amphetamine concentrations (2, 4, 5) . The percentage of fenproporex metabolized to amphetamine in this study was 27-34%. This is virtually identical to the percentages reported for samples collected without acidification of the urine in a previous study (2) .
In a previous study, Beckett et al. (4) showed amphetamine to be a metabolite of fenproporex. The dose in this study was 16.71 mg of fenproporex administered by mouth. When the urine pH was controlled by acidification, 5.4-8.7% of the dose was excreted unchanged and could be detected for 14 h postdose. Amphetamine accounted for 34.2-55.9% of the dose (n = 3). The same oral dose of fenproporex without urine pH control resulted in approximately 3% of the drug being excreted unchanged and being detected for only 2 h. Amphetamine made up 29.3--47.4% of the dose and could be detected for only seven hours (n = 2). In another study, a 2.54-mg oral dose of fenproporex was administered to two subjects. In 24 h, 26.9-31.4% of the dose was excreted as amphetamine. The authors indicated that the rate of excretion of amphetamine was similar to a equal dose of amphetamine (2) . Results of the present study differ from the conclusions of the previous studies in several significant ways. The most significant of these is fenproporex could be detected for substantially longer periods of time than previously reported. With all five experimental subjects, all urine samples that contained amphetamine at concentrations of greater than or equal to 500 ng/mL also had detectable amounts of fenproporex.
Direct comparison with previous studies is difficult because one study only quantitated the drug for the first 24 h, and then only as total amount excreted during 0-4-, 4-8-, and 8--24-h periods (2) . That study did not measure the concentration of fenproporex in the urine samples, but rather compared the amphetamine levels with what would be expected from administration of amphetamine directly. The study that did quantitate fenproporex used a GC method but did not indicate the detection limit of the assay. They did indicate that the fenproporex calibration curve was from 200 to 10,000 ng/mL, and the short detection time may be the result of lack of sensitivity of the assay. Administration of fenproporex results in urinary excretion of amphetamine. A single dose of the drug can result in detectable levels of amphetamine for up to 119:20 h postdose. Peak concentrations reached as high as 2099 ng/mL for amphetamine. Interpretation of analytical results can be extremely helpful in determining the possibility of involvement of this drug in the subject. The fact that the amphetamine is racemic helps in the interpretation because the presence of only the d-enantiomer would be inconsistent with use of this drug. Unfortunately, unlike methamphetamine, where the vast majority of the illicit drug is the d enantiomer, a substantial amount of illicit amphetamine is racemic. The presence of the parent compound and its relative concentra-9 24.00 tion can be conclusive evidence for the involvement of this drug. The fact that all samples containing amphetamine at or above the Health and Human Services (HHS) mandatory cutoff of 500 ng/mL showed detectable amounts of the parent drug makes the involvement of this drug much easier to access than previously indicated in the literature. Unfortunately, current HHS guidelines prevent testing for any drugs other than those specified in the guidelines with the ex-. . . . ception of"for cause" testing of drugs under Schedule I or II. As a result, testing for the parent fenproporex in samples falling under those regulations can not be accomplished.
Conclusion
Other testing programs, however, are not limited in that regard, and can therefore test for the parent to assess the potential of fenproporex being the origin of amphetamine if the question arises. 
